SSTR4 Antibody

What is SSTR4 and where is it primarily expressed?

SSTR4 (somatostatin receptor type 4) is a member of the G-protein coupled receptor 1 protein family that functions as a receptor for somatostatin-14. The human canonical protein has 388 amino acid residues and a mass of 42 kDa, with subcellular localization in the cell membrane. It is prominently expressed in the fetal and adult brain, lung tissue, and stomach, with lower expression levels in the kidney, pituitary, and adrenal glands . In the brain, SSTR4 shows high expression in infragranular cortical layers and lower expression in supragranular layers, with strong presence in cortical pyramidal cells and hippocampal areas CA1-CA3 . SSTR4 is also expressed in trigeminal ganglia, primarily in small to medium-diameter neurons, and in various other tissues including the adrenal cortex, exocrine pancreas, and syncytiotrophoblasts of the placenta .

How can I determine the specificity of an SSTR4 antibody?

Confirming antibody specificity is crucial for reliable research results. For SSTR4 antibodies, implement a multi-step validation approach:

• Western blot validation: Compare immunoblot results from SSTR4-transfected cells versus mock-transfected cells. A specific antibody should detect a band at approximately 50-60 kDa (glycosylated receptor) only in SSTR4-transfected samples .

• Peptide competition assay: Pre-incubate the antibody with its immunizing peptide before immunostaining. Complete extinction of the immunosignal confirms specificity .

• Cross-validation: Compare staining patterns across different detection methods. For example, compare anti-SSTR4 antibody staining in human tissues with eGFP staining patterns in SSTR4-eGFP knockin mice .

• Genetic controls: Use tissue from SSTR4 knockout models as negative controls when available.

• Expression pattern verification: Confirm that observed staining matches known SSTR4 distribution, such as strong signals in cortical pyramidal cells, trigeminal ganglia, and adrenal cortex .

What are the most common applications for SSTR4 antibodies?

SSTR4 antibodies are employed across multiple experimental applications, with Western Blot and Immunohistochemistry being the most widely used . These applications serve various research objectives:

• Western Blot (WB): Primarily used for quantitative detection and semi-quantitative analysis of SSTR4 protein levels in tissue or cell lysates. This technique allows researchers to determine SSTR4 expression changes under different experimental conditions or disease states.

• Immunohistochemistry (IHC): Enables visualization of SSTR4 cellular and subcellular localization in tissue sections. In human tissues, SSTR4 immunostaining is typically observed in both plasma membrane and cytoplasm .

• Enzyme-Linked Immunosorbent Assay (ELISA): Used for quantitative measurement of SSTR4 protein in solution.

• Immunofluorescence (IF): Allows for high-resolution imaging of SSTR4 localization and potential co-localization with other proteins.

• Flow Cytometry: Enables quantification of SSTR4 expression in individual cells within heterogeneous populations.

Each application requires specific antibody properties, so researchers should select antibodies validated for their intended application.

What are the known challenges when using SSTR4 antibodies?

Researchers working with SSTR4 antibodies face several significant challenges:

• Antibody specificity concerns: The specificity of SSTR4 antibodies, particularly polyclonal ones, has been questioned in multiple studies . Many commercially available antibodies may cross-react with other somatostatin receptor subtypes or unrelated proteins.

• Variability between species: SSTR4 antibodies may show different specificity and sensitivity across species. While orthologs have been reported in mouse, rat, frog, chimpanzee, and chicken , antibodies raised against human SSTR4 may not recognize these orthologs with equal efficiency.

• Post-translational modifications: SSTR4 undergoes glycosylation , which can affect antibody binding. The glycosylation pattern may vary between tissues and experimental conditions.

• Limited detection sensitivity: In tissues with low SSTR4 expression, standard immunodetection methods may be insufficient to detect the protein reliably.

• Membrane protein solubilization: As a membrane protein, SSTR4 can be difficult to extract and maintain in its native conformation during sample preparation, potentially affecting antibody recognition.

To overcome these challenges, researchers should use antibodies with comprehensive validation data and consider complementary detection methods such as mRNA analysis.

How can I optimize immunohistochemical staining for SSTR4?

Optimizing immunohistochemical staining for SSTR4 requires careful attention to several parameters:

• Fixation protocol: Use 10% neutral buffered formalin for tissue fixation. Overfixation may mask epitopes, while inadequate fixation can lead to poor tissue morphology.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is often effective for SSTR4 detection. Compare different retrieval methods to determine optimal conditions.

• Blocking procedure: Use 5-10% normal serum from the same species as the secondary antibody plus 1% BSA to reduce nonspecific binding. For tissues with high endogenous biotin, include an avidin-biotin blocking step.

• Antibody dilution and incubation: Start with the manufacturer's recommended dilution and optimize through a dilution series. For novel antibodies like the monoclonal rabbit anti-human SST4 antibody 7H49L61, careful optimization is essential as it has proven effective for detecting membrane and cytoplasmic SSTR4 .

• Detection system selection: Polymer-based detection systems often provide better signal-to-noise ratio than traditional ABC methods for SSTR4.

• Controls: Always include positive controls (tissues known to express SSTR4, such as cerebral cortex or adrenal cortex) and negative controls (antibody diluent without primary antibody) in each experiment .

How does SSTR4 promoter methylation relate to alcohol dependence?

Recent epigenetic research has uncovered a significant relationship between SSTR4 promoter methylation and alcohol dependence (AD). A study of 63 subjects with AD and 65 healthy controls revealed that methylation levels of the SSTR4 promoter region were significantly lower in the AD group compared to controls (two-tailed t-test, t = 14.723, p < 0.001) . This hypomethylation pattern appears to be specific to alcohol dependence, suggesting potential involvement in the development and persistence of AD.

The study demonstrated negative correlations between SSTR4 promoter methylation levels and various alcohol dependence-related scales:

These findings suggest that SSTR4 promoter hypomethylation could serve as a potential biomarker for alcohol dependence and might represent a novel therapeutic target. The relationship appears to be mediated through gene-environment interactions, with heavy drinking potentially altering epigenetic modifications that subsequently promote AD development .

What is known about SSTR4 expression in human tumors?

SSTR4 expression in human tumors has been documented in numerous studies, though with varying patterns and significance:

• Expression frequency: SSTR4 is often co-expressed with other somatostatin receptor family members in tumors, but typically at lower levels compared to other SST subtypes .

• Subcellular localization: In tumor samples, SSTR4 immunostaining is predominantly cytoplasmic rather than membranous, which differs from the normal tissue distribution pattern where both membrane and cytoplasmic localization is observed .

• Tumor types: Studies have investigated SSTR4 expression across multiple tumor types, including neuroendocrine tumors, pituitary adenomas, gliomas, and various carcinomas.

• Diagnostic implications: The expression profile of somatostatin receptors, including SSTR4, can help in tumor characterization and selection of appropriate somatostatin analog therapy.

• Technical considerations: Questions regarding antibody specificity have complicated the interpretation of SSTR4 expression in tumors, with some authors noting concerns about the reliability of polyclonal antibodies used for detection .

The development of the novel rabbit monoclonal anti-human SST4 antibody (7H49L61) provides a more reliable tool for assessing SSTR4 expression in human tumor samples, potentially enabling more accurate diagnostic and prognostic assessments .

How do SSTR4-eGFP knockin mouse models advance our understanding of SSTR4 biology?

The development of SSTR4-eGFP knockin mouse models represents a significant methodological advancement in SSTR4 research, addressing the previous limitation of suitable specific antibodies for localization studies . These models offer several distinct advantages:

• Enhanced visualization: The eGFP tag enables direct visualization of SSTR4 expression through fluorescence microscopy or by using anti-GFP antibodies, which typically have higher specificity than anti-SSTR4 antibodies.

• Precise localization: Studies using these models have revealed detailed expression patterns, showing strong SSTR4 presence in cortical pyramidal cells, hippocampal areas CA1-CA3, amygdala neurons, and various peripheral tissues including the adrenal cortex and exocrine pancreas .

• Correlation with mRNA expression: By comparing eGFP fluorescence with in situ hybridization results, researchers have confirmed that protein expression patterns closely match mRNA distribution, validating the model's accuracy in representing endogenous SSTR4 expression .

• Negative control availability: Wild-type mice lacking SST4-eGFP expression serve as perfect negative controls, allowing researchers to distinguish between specific and non-specific signals .

• Cross-species validation: These models enable comparative studies between mouse and human tissues, facilitating translation of findings across species and validation of antibodies for human tissue applications .

This approach has revealed previously uncharacterized expression patterns, such as the differential expression in hippocampal regions (high in pyramidal cells but low in dentate gyrus granule cells) and the selective expression in small to medium-diameter neurons in trigeminal ganglia .

What are the functional implications of SSTR4 expression in specific brain regions?

The distinctive expression pattern of SSTR4 in neural tissues suggests important functional roles in neurophysiology:

• Cortical pyramidal cells: The strong expression in infragranular cortical layers and pyramidal cells suggests involvement in modulating cortical output signals. SSTR4 likely contributes to inhibitory control of excitatory neurotransmission in these projection neurons, potentially affecting cognitive processes and motor control .

• Hippocampal regions: The differential expression pattern between hippocampal areas (high in CA1-CA3 pyramidal cells but low in dentate gyrus granule cells) implies region-specific roles in memory formation and consolidation processes. SSTR4 activation may modulate synaptic plasticity differently across hippocampal circuits .

• Trigeminal ganglia: Expression in small to medium-diameter neurons of trigeminal ganglia suggests involvement in somatosensory processing, particularly nociception. SSTR4 may participate in pain modulation through inhibition of nociceptive transmission in these primary sensory neurons .

• Amygdala: SSTR4 expression in amygdala neurons indicates potential roles in emotional processing, fear conditioning, and stress responses. This aligns with findings linking SSTR4 methylation levels to stress profiles in alcohol-dependent individuals .

These expression patterns collectively suggest that SSTR4 contributes to multiple aspects of neuronal signaling and may represent a target for neurological and psychiatric conditions, particularly those involving stress responses and substance dependence .

What experimental approaches can help resolve contradictory findings regarding SSTR4 function?

Contradictory findings in SSTR4 research can be addressed through several methodological approaches:

• Genetic validation models:

  • Use SSTR4 knockout models to confirm phenotypes attributed to SSTR4

  • Employ conditional knockout systems to study tissue-specific functions

  • Validate with SSTR4-eGFP knockin models that maintain functional integrity

• Pharmacological validation:

  • Utilize highly selective SSTR4 agonists and antagonists

  • Compare effects with pan-somatostatin analogs

  • Perform dose-response studies to establish specificity

• Multi-omics integration:

  • Correlate transcriptomics, proteomics, and epigenomics data

  • Analyze the methylation-expression relationship, as demonstrated in alcohol dependence studies

  • Integrate findings across different experimental systems

• Improved detection methodologies:

  • Employ multiple antibodies targeting different epitopes

  • Use both monoclonal antibodies (like 7H49L61) and polyclonal antibodies with proper validation

  • Combine protein detection with mRNA localization through in situ hybridization

• Standardized reporting:

  • Document detailed experimental conditions

  • Report antibody validation procedures

  • Include appropriate positive and negative controls

  • Specify exact cellular and subcellular localization

By implementing these approaches, researchers can better reconcile conflicting reports and establish more consistent understanding of SSTR4 biology across different experimental systems and disease contexts.

How should I design an experiment to study SSTR4 promoter methylation?

Designing a robust experiment to study SSTR4 promoter methylation requires careful consideration of multiple factors:

• Sample collection and processing:

  • Collect peripheral blood samples in EDTA tubes for DNA extraction

  • Process samples consistently to minimize technical variation

  • Consider using paired samples (e.g., case-control or pre-post intervention) to increase statistical power

• Methylation detection method selection:

  • For hypothesis-driven studies focusing specifically on SSTR4, pyrosequencing offers high quantitative accuracy for targeted CpG sites, as demonstrated in alcohol dependence research

  • For discovery-phase research, consider genome-wide approaches like Illumina BeadChip arrays followed by validation with pyrosequencing

  • For single-cell resolution, bisulfite sequencing combined with next-generation sequencing provides comprehensive coverage

• Experimental design considerations:

  • Include sufficient biological replicates (minimum n=30 per group based on previous studies)

  • Control for confounding factors such as age, sex, medication, and environmental exposures

  • Use appropriate statistical methods for methylation data, typically linear regression models for correlation analyses

• Data analysis and interpretation:

  • Compare methylation levels between experimental groups using appropriate statistical tests (e.g., two-tailed t-test)

  • Correlate methylation levels with relevant clinical parameters using linear regression analysis

  • Visualize relationships using scatter plots and bubble plots as demonstrated in alcohol dependence research

• Functional validation:

  • Correlate methylation with gene expression levels when possible

  • Consider using in vitro methylation assays with reporter constructs to establish causality

This methodological approach has successfully identified hypomethylation of the SSTR4 promoter in alcohol-dependent individuals and established correlations with clinical measures .

What are the best practices for validating a novel anti-SSTR4 antibody?

Comprehensive validation of a novel anti-SSTR4 antibody requires a systematic multi-step approach:

• Expression system validation:

  • Test antibody reactivity in SST4-transfected versus mock-transfected cell lines (e.g., HEK-293 cells)

  • Confirm detection of the expected molecular weight band (50-60 kDa for glycosylated SSTR4) in immunoblots

  • Verify absence of signal in cells lacking SSTR4 expression

• Peptide competition assay:

  • Pre-incubate antibody with its immunizing peptide before application

  • Confirm complete extinction of immunosignal in both Western blot and immunohistochemistry applications

  • Use varying peptide concentrations to establish specificity threshold

• Cross-species reactivity assessment:

  • Test antibody against SSTR4 from different species when cross-reactivity is claimed

  • Compare staining patterns with known species-specific expression profiles

  • For human-specific antibodies like 7H49L61, compare with expression patterns in animal models (e.g., SST4-eGFP knockin mice)

• Application-specific validation:

  • For immunohistochemistry: Test on multiple tissue types with known SSTR4 expression patterns

  • For Western blot: Optimize protein extraction, denaturation and separation conditions

  • For flow cytometry: Establish appropriate fixation and permeabilization protocols

• Reproducibility testing:

  • Assess batch-to-batch consistency

  • Test under varying experimental conditions

  • Compare with independent detection methods like mRNA in situ hybridization

This validation approach was successfully applied to the novel rabbit monoclonal anti-human SST4 antibody 7H49L61, establishing it as a reliable tool for both immunoblot analysis and immunohistochemical applications .

How can I differentiate between SSTR4 and other somatostatin receptor subtypes in my experiments?

Distinguishing SSTR4 from other somatostatin receptor subtypes requires a combination of selective approaches:

• Subtype-specific antibodies:

  • Use well-validated monoclonal antibodies with demonstrated specificity like 7H49L61 for human SSTR4

  • Verify antibody specificity through peptide competition assays and testing on expression systems

  • Employ multiple antibodies targeting different epitopes when possible

• Selective pharmacological tools:

  • Utilize SSTR4-selective agonists (e.g., L-803,087) and antagonists

  • Compare responses to pan-somatostatin analogs versus subtype-selective compounds

  • Implement dose-response studies to identify receptor subtype-specific pharmacological profiles

• Genetic approaches:

  • Use SSTR4 knockout models or siRNA-mediated knockdown as negative controls

  • Employ reporter gene systems with subtype-specific promoters

  • Utilize SSTR4-eGFP knockin models for direct visualization of specific subtype expression

• Comparative expression analysis:

  • Compare expression patterns across tissues known to differentially express SST subtypes

  • SSTR4 shows distinctive expression in cortical pyramidal cells, adrenal cortex, and exocrine pancreas

  • Other subtypes show different distribution patterns (e.g., SSTR2 in pancreatic islets where SSTR4 is absent)

• mRNA detection methods:

  • Design highly specific primers or probes for RT-PCR or in situ hybridization

  • Use hybridization conditions that minimize cross-reactivity between closely related subtypes

  • Verify specificity with positive and negative control tissues

These approaches can be combined in complementary fashion to ensure reliable differentiation between somatostatin receptor subtypes in experimental systems.

What are the optimal conditions for Western blot detection of SSTR4?

Optimizing Western blot conditions for SSTR4 detection requires addressing the challenges associated with this membrane receptor protein:

• Sample preparation:

  • Use specialized membrane protein extraction buffers containing 1-2% detergent (e.g., RIPA buffer with additional 1% Triton X-100)

  • Add protease inhibitor cocktail to prevent degradation

  • For glycosylated SSTR4 studies, consider using PNGase F treatment of a portion of samples to distinguish between glycosylated (50-60 kDa) and non-glycosylated forms

  • Avoid boiling samples to prevent membrane protein aggregation; instead, incubate at 37°C for 30 minutes

• Gel electrophoresis parameters:

  • Use 10-12% polyacrylamide gels for optimal resolution of the 42-60 kDa range

  • Load 30-50 μg of total protein per lane for endogenous detection

  • Include positive controls from SSTR4-transfected cell lines

  • Run at lower voltage (80-100V) to improve resolution

• Transfer conditions:

  • Perform wet transfer at 30V overnight at 4°C for efficient transfer of membrane proteins

  • Use PVDF membranes with 0.45 μm pore size for optimal protein binding

  • Add 0.1% SDS to transfer buffer to improve elution of hydrophobic proteins from gel

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST for 1-2 hours at room temperature

  • For primary antibody incubation, use validated antibodies like the rabbit monoclonal anti-human SST4 antibody 7H49L61 at optimized dilutions

  • Incubate primary antibody overnight at 4°C with gentle rocking

  • Use TBS-T with 1% milk for antibody dilution and washing steps

• Detection system:

  • Employ high-sensitivity chemiluminescent substrates for enhanced detection

  • Consider using signal enhancers specifically designed for membrane proteins

  • Use gradual exposure times to optimize signal-to-noise ratio

These optimized conditions should yield a clear band at 50-60 kDa for glycosylated SSTR4, as demonstrated in studies using the 7H49L61 antibody on SSTR4-transfected HEK-293 cells .

How can I design experiments to investigate SSTR4's role in alcohol dependence?

Based on recent findings linking SSTR4 promoter methylation to alcohol dependence , designing comprehensive experiments to investigate this relationship requires a multi-faceted approach:

• Epigenetic profiling:

  • Analyze SSTR4 promoter methylation in larger cohorts of alcohol-dependent individuals and matched controls

  • Implement longitudinal sampling to track methylation changes during alcohol use, withdrawal, and relapse

  • Compare methylation patterns across different tissues when ethically possible (e.g., blood vs. buccal cells)

  • Correlate methylation levels with standardized alcohol dependence scales (AUDIT, LES, WSS)

• Functional studies:

  • Investigate how methylation affects SSTR4 gene expression using reporter assays

  • Examine the effects of alcohol exposure on SSTR4 expression in cellular and animal models

  • Utilize SSTR4 knockout or knockdown models to assess alcohol consumption behavior

  • Test SSTR4-selective compounds for effects on alcohol preference and withdrawal symptoms

• Clinical correlation studies:

  • Design case-control studies with larger sample sizes (minimum n=100 per group)

  • Implement careful matching for confounding variables (age, sex, ethnicity, comorbidities)

  • Develop standardized protocols for assessing the relationship between SSTR4 methylation and:

    • Alcohol craving intensity

    • Withdrawal severity

    • Relapse risk

    • Response to treatment interventions

• Translational research approaches:

  • Develop SSTR4 methylation assays with potential for clinical application

  • Investigate whether SSTR4 methylation status predicts treatment outcomes

  • Test whether interventions affecting SSTR4 function modify alcohol consumption patterns

  • Examine potential pharmacological targeting of SSTR4 or its methylation status as therapeutic approach

• Integrated multi-omics approach:

  • Combine methylation analysis with transcriptomics, proteomics, and metabolomics

  • Apply machine learning algorithms to identify patterns and predictors of alcohol dependence

  • Develop comprehensive models incorporating genetic and epigenetic SSTR4 variations

These experimental approaches would address the limitations noted in current research and potentially establish SSTR4 as a clinically relevant biomarker and therapeutic target for alcohol dependence.

What are the implications of SSTR4 tissue distribution for developing targeted therapies?

The detailed characterization of SSTR4 tissue distribution using both the SST4-eGFP knockin mouse model and the rabbit monoclonal anti-human SST4 antibody has revealed a distinctive expression pattern with significant therapeutic implications :

• Neurological applications:

  • The high expression in cortical pyramidal cells and hippocampal regions suggests potential targets for cognitive disorders and epilepsy

  • SSTR4 in trigeminal ganglia neurons indicates possible applications for migraine and facial pain conditions

  • Expression in amygdala neurons suggests relevance for anxiety disorders and stress-related conditions, potentially connecting to findings in alcohol dependence

• Endocrine system targeting:

  • Strong expression in all three layers of the adrenal cortex suggests potential for modulating steroid hormone production

  • Differential expression between anterior and posterior pituitary indicates selective targeting possibilities within the hypothalamic-pituitary axis

• Gastrointestinal applications:

  • Expression in pancreatic exocrine tissue but absence in pancreatic islets allows for selective targeting of exocrine versus endocrine pancreatic functions

  • Presence in intestinal ganglia, gastric fundic glands, and duodenal epithelium suggests applications for gastrointestinal motility and secretory disorders

• Renal system considerations:

  • Predominant expression in distal tubules with lower expression in proximal tubules and mesangial cells indicates potential for targeted kidney disease therapies

• Delivery strategy implications:

  • The distinct subcellular localization patterns (membrane versus cytoplasmic) across different tissues necessitate tailored drug delivery approaches

  • Absence in immune tissues (spleen, lymph nodes, bone marrow) suggests minimal direct immunomodulatory effects of SSTR4-targeted therapies

This detailed mapping enables more precise prediction of both on-target effects and potential side effects of SSTR4-targeted therapeutic approaches.

How might epigenetic regulation of SSTR4 impact its function across different physiological states?

The discovery of SSTR4 promoter methylation changes in alcohol dependence opens a broader investigation into epigenetic regulation of this receptor:

• Dynamic regulation mechanisms:

  • Methylation changes may serve as a responsive mechanism to environmental factors, as suggested by the correlation between hypomethylation and alcohol exposure

  • Other epigenetic marks (histone modifications, non-coding RNAs) likely work in concert with DNA methylation to fine-tune SSTR4 expression

• Tissue-specific epigenetic profiles:

  • Different tissues may maintain distinct SSTR4 methylation patterns explaining the heterogeneous expression observed across brain regions and peripheral tissues

  • Developmental stages likely feature dynamic epigenetic reprogramming of SSTR4, potentially explaining differences between fetal and adult expression patterns

• Stress response modulation:

  • The correlation between SSTR4 methylation and stress scales (WSS, R² = 0.49) suggests epigenetic regulation may link stress exposure to altered SSTR4 function

  • This mechanism could explain how chronic stress impacts systems where SSTR4 is prominently expressed, such as the adrenal cortex and amygdala

• Disease-specific alterations:

  • Beyond alcohol dependence, other conditions may feature distinctive SSTR4 methylation signatures

  • These epigenetic changes could contribute to pathological alterations in somatostatin signaling observed in various neurological and psychiatric disorders

• Transgenerational considerations:

  • If SSTR4 methylation changes persist in germline cells, they could potentially contribute to inherited risk for conditions like alcohol dependence

  • This possibility warrants investigation of transgenerational effects in animal models and human cohorts

Understanding these epigenetic regulatory mechanisms could lead to novel therapeutic approaches targeting the epigenetic control of SSTR4 rather than the receptor itself.